A detailed history of Rhumbline Advisers transactions in Amneal Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 224,389 shares of AMRX stock, worth $1.87 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
224,389
Previous 233,217 3.79%
Holding current value
$1.87 Million
Previous $1.48 Million 26.08%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$6.42 - $8.83 $56,675 - $77,951
-8,828 Reduced 3.79%
224,389 $1.87 Million
Q2 2024

Aug 01, 2024

BUY
$5.36 - $7.11 $162,332 - $215,333
30,286 Added 14.92%
233,217 $1.48 Million
Q1 2024

May 09, 2024

SELL
$5.24 - $6.34 $51,666 - $62,512
-9,860 Reduced 4.63%
202,931 $1.23 Million
Q4 2023

Feb 08, 2024

BUY
$3.36 - $6.21 $44,976 - $83,127
13,386 Added 6.71%
212,791 $1.29 Million
Q3 2023

Nov 09, 2023

BUY
$2.76 - $4.59 $1,719 - $2,859
623 Added 0.31%
199,405 $841,000
Q2 2023

Aug 08, 2023

BUY
$1.33 - $3.1 $48,674 - $113,450
36,597 Added 22.56%
198,782 $616,000
Q1 2023

May 11, 2023

BUY
$1.27 - $2.7 $2,123 - $4,514
1,672 Added 1.04%
162,185 $225,000
Q4 2022

Feb 14, 2023

BUY
$1.96 - $2.61 $9,529 - $12,689
4,862 Added 3.12%
160,513 $319,000
Q3 2022

Nov 10, 2022

BUY
$2.02 - $3.62 $18,038 - $32,326
8,930 Added 6.09%
155,651 $314,000
Q2 2022

Aug 11, 2022

BUY
$3.01 - $4.46 $6,438 - $9,539
2,139 Added 1.48%
146,721 $467,000
Q1 2022

May 12, 2022

SELL
$3.9 - $4.89 $53,196 - $66,699
-13,640 Reduced 8.62%
144,582 $603,000
Q4 2021

Feb 10, 2022

BUY
$3.95 - $5.85 $22,467 - $33,274
5,688 Added 3.73%
158,222 $758,000
Q3 2021

Nov 12, 2021

BUY
$4.31 - $5.64 $12,662 - $16,570
2,938 Added 1.96%
152,534 $815,000
Q2 2021

Aug 05, 2021

SELL
$5.12 - $6.82 $23,828 - $31,740
-4,654 Reduced 3.02%
149,596 $766,000
Q1 2021

May 06, 2021

SELL
$4.74 - $7.38 $32,198 - $50,132
-6,793 Reduced 4.22%
154,250 $1.04 Million
Q4 2020

Feb 10, 2021

BUY
$3.95 - $5.42 $28,795 - $39,511
7,290 Added 4.74%
161,043 $736,000
Q3 2020

Nov 12, 2020

SELL
$3.54 - $5.27 $83,154 - $123,792
-23,490 Reduced 13.25%
153,753 $597,000
Q2 2020

Aug 13, 2020

BUY
$2.87 - $5.46 $63,820 - $121,414
22,237 Added 14.35%
177,243 $844,000
Q1 2020

May 06, 2020

BUY
$2.46 - $5.35 $19,648 - $42,730
7,987 Added 5.43%
155,006 $539,000
Q4 2019

Feb 05, 2020

BUY
$2.65 - $5.56 $44,710 - $93,808
16,872 Added 12.96%
147,019 $709,000
Q3 2019

Oct 23, 2019

SELL
$2.29 - $7.1 $1,706 - $5,289
-745 Reduced 0.57%
130,147 $377,000
Q2 2019

Aug 14, 2019

BUY
$6.44 - $14.29 $45,350 - $100,630
7,042 Added 5.69%
130,892 $938,000
Q1 2019

May 01, 2019

SELL
$11.87 - $14.84 $17,330 - $21,666
-1,460 Reduced 1.17%
123,850 $1.76 Million
Q4 2018

Jan 31, 2019

BUY
$13.09 - $21.49 $493,663 - $810,452
37,713 Added 43.05%
125,310 $1.7 Million
Q3 2018

Nov 07, 2018

SELL
$16.4 - $24.27 $93,233 - $137,974
-5,685 Reduced 6.09%
87,597 $1.94 Million
Q2 2018

Aug 06, 2018

BUY
$13.95 - $20.2 $1.3 Million - $1.88 Million
93,282 New
93,282 $1.53 Million

Others Institutions Holding AMRX

About Amneal Pharmaceuticals, Inc.


  • Ticker AMRX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 151,408,992
  • Market Cap $1.26B
  • Description
  • Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and comme...
More about AMRX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.